Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 162 of the 165 references it cites were found in a registry or an index; 194 of the 302 sources its claims cite were checked for support.

Epidemiology of Invasive Candidiasis

Open access
Bays, Derek, Jenkins, Emily, Lyman, Meghan, Chiller, Tom, Strong, Nora, Ostrosky-Zeichner, Luis, Hoenigl, Martin, Pappas, Peter, Thompson, George · 2024 · Clinical Epidemiology

Abstract

Invasive candidiasis (IC) is an increasingly prevalent, costly, and potentially fatal infection brought on by the opportunistic yeast, Candida . Previously, IC has predominantly been caused by C. albicans which is often drug susceptible. There has been a global trend towards decreasing rates of infection secondary to C. albicans and a rise in non- albicans species with a corresponding increase in drug resistance creating treatment challenges. With advances in management of malignancies, there has also been an increase in the population at risk from IC along with a corresponding increase in incidence of breakthrough IC infections. Additionally, the emergence of C. auris creates many challenges in management and prevention due to drug resistance and the organism’s ability to transmit rapidly in the healthcare setting. While the development of novel antifungals is encouraging for future management, understanding the changing epidemiology of IC is a vital step in future management and prevention. Keywords: Candida, epidemiology, resistance, emerging, non- albicans Candida species

Overview

CoChat Summary

TL;DR

Invasive candidiasis remains a costly, morbid, and often fatal infection, with declining *C. albicans* proportions, rising non-albicans species, antifungal resistance, breakthrough infections, and the emergence of multidrug-resistant *C. auris*. This review synthesizes global epidemiology, diagnostics, burden, species distribution, resistance trends, management, and prevention.

Key findings

  • Candidemia causes an estimated 22,000 infections annually in the United States and is the second most common healthcare-associated bloodstream infection nationally; all-cause in-hospital mortality has been reported as high as 36% in the US, 38–42% at 30 days in Europe, ~40% in Asia, 33–60% in MENA, and 30–70% in South America.
  • The proportion of *C. albicans* has fallen from 70–80% in the 1980–1990s to 40–60% in most areas; in ECMM studies, *C. albicans* decreased from 56.4% (1997–1999) to 54% (2006–2008) to 46.0% (2018), while *C. glabrata* rose from 13.9% to 21.0%.
  • Resistance is increasing: CDC surveys report *C. glabrata* fluconazole resistance of 7–11% and echinocandin resistance of 2–8%; *C. parapsilosis* fluconazole resistance exceeds 50% in some series and is 4–10% in the US; *C. auris* shows fluconazole resistance in 70–90% of isolates, echinocandin resistance up to 7%, amphotericin B resistance up to 35%, and pan-resistance most commonly in India/South Asia (3%).
  • Breakthrough *Candida* infections occur in fewer than 10% of at-risk patients but can constitute up to 40% of all *Candida* infections in selected series; 30-day mortality is similar to de novo infections (~30%). Blood cultures have only ~50% sensitivity for invasive candidiasis; T2Candida has 91% sensitivity and 94% specificity, while 1,3-β-D-glucan sensitivity averages ~85% but specificity is often below 60%.

Methods

  • Narrative review of invasive candidiasis epidemiology, diagnostics, burden, geographic species differences, emerging species, breakthrough infections, antifungal susceptibility, management, antifungal pipeline, and infection control.
  • Evidence is drawn from published literature, including population-based surveillance, meta-analyses, multicenter ECMM/SENTRY/CDC/TRANSNET studies, clinical trials, and guidelines; no new primary data are presented.
  • Main analysis is qualitative synthesis; no systematic review search strategy, risk-of-bias assessment, or quantitative pooling is described.

Limitations

  • Stated: current diagnostics have limited sensitivity/specificity that affect epidemiologic assessment; intra-abdominal candidiasis lacks standardized definitions; there are no population-based data sources for Asia, the Middle East, Africa, or Latin America; most IC studies are single-center or smaller multicenter analyses; candidemia is generally not reportable, so reporting is voluntary; lack of standardized methodologies and denominators limits comparisons.
  • Stated: the overall burden of IC is likely underestimated because of global surveillance gaps and diagnostic performance limitations.
  • Evident: as a narrative review, it does not provide a systematic search, formal quality appraisal, or quantitative synthesis, so conclusions may inherit publication and surveillance biases from the cited literature.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.2147/clep.s459600

Cites

162 of 162 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Common risk factors for invasive candidiasis. Risk factors: intravenous catheters, total parental nutrition, post-procedure, broad-spectrum antibiotics, colonization at non-sterile sites, chemotherapy, transplant recipients.
Figure 1 Common risk factors for invasive candidiasis. Risk factors: intravenous catheters, total parental nutrition, post-procedure, broad-spectrum antibiotics, colonization at non-sterile sites, chemotherapy, transplant recipients.CC BY-NC · PubMed Central

Verification

Claims the paper makes

104 Valid · 10 Not valid · 40 Not checked · 16 Own results and interpretations

90 more claims · 59 with their cited sources checked

Create a free account to see all 170 claims and to verify the 4 references still open.

See all claims — free account
  • Probably not a substantial claim. 25
  • It may state two separate claims as one. 58

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 165 references

Research works printed but not linked: 2

  1. Ulrych, 2020, Epidemiol Mikrobiol Imunol, 69, 57
  2. 2020, Clinical Practice of Medical Mycology in Asia

Cited by

See all 109

Metadata

Authors
Bays, D., Jenkins, E., Lyman, M., Chiller, T., Strong, N., Ostrosky-Zeichner, L., Hoenigl, M., Pappas, P., & Thompson, G.
Affiliations
  • University of California Davis Medical Center (US)
  • Centers for Disease Control and Prevention (US)
  • The University of Texas Health Science Center at Houston (US)
  • Medical University of Graz (AT)
  • University of Alabama at Birmingham (US)
Corresponding author
Bays, Derek
Venue
Clinical Epidemiology
Published
2024-08
Volume
Volume 16
Pages
549-566
ISSN
1179-1349 (ISSN-L)
OpenAlex
W4401967436
Cited by
109
References
165
Citations by year
2026: 62 · 2025: 42 · 2024: 2
FWCI
8.81
Type
journal article
Language
en
Open access
Locations
  • Clinical Epidemiology (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Digital Commons-TMC (Texas Medical Center) (submittedVersion, other-oa)
  • eScholarship (California Digital Library) (submittedVersion, cc-by-nc)
  • Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
Funders
  • National Institutes of Health (UL1TR001860, KL2TR001859)
  • National Center for Advancing Translational Sciences
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Life Sciences › Immunology and Microbiology › Microbiology › Yeasts and Rust Fungi Studies
  • Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
Keywords
invasive candidiasis, Candida albicans, non-albicans Candida, Candida auris, antifungal resistance, opportunistic fungal infection, emerging fungal pathogens, antifungal agents, nosocomial transmission, cancer patients

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Epidemiology of Invasive Candidiasis. https://app.cochat.ai/papers/10.2147/clep.s459600
The paper
Bays, D., Jenkins, E., Lyman, M., Chiller, T., Strong, N., Ostrosky-Zeichner, L., Hoenigl, M., Pappas, P., & Thompson, G. (2024). Epidemiology of Invasive Candidiasis. Clinical Epidemiology. https://doi.org/10.2147/clep.s459600

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.